These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27943071)

  • 1. Analysis of Melanin-like Pigment Synthesized from Homogentisic Acid, with or without Tyrosine, and Its Implications in Alkaptonuria.
    Taylor AM; Vercruysse KP
    JIMD Rep; 2017; 35():79-85. PubMed ID: 27943071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone.
    Preston AJ; Keenan CM; Sutherland H; Wilson PJ; Wlodarski B; Taylor AM; Williams DP; Ranganath LR; Gallagher JA; Jarvis JC
    Ann Rheum Dis; 2014 Jan; 73(1):284-9. PubMed ID: 23511227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homogentisic acid induces morphological and mechanical aberration of ochronotic cartilage in alkaptonuria.
    Bernardini G; Leone G; Millucci L; Consumi M; Braconi D; Spiga O; Galderisi S; Marzocchi B; Viti C; Giorgetti G; Lupetti P; Magnani A; Santucci A
    J Cell Physiol; 2019 May; 234(5):6696-6708. PubMed ID: 30341892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel ex vivo organotypic culture model of alkaptonuria-ochronosis.
    Tinti L; Spreafico A; Chellini F; Galeazzi M; Santucci A
    Clin Exp Rheumatol; 2011; 29(4):693-6. PubMed ID: 21813063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitisinone Arrests but Does Not Reverse Ochronosis in Alkaptonuric Mice.
    Keenan CM; Preston AJ; Sutherland H; Wilson PJ; Psarelli EE; Cox TF; Ranganath LR; Jarvis JC; Gallagher JA
    JIMD Rep; 2015; 24():45-50. PubMed ID: 25940034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alkaptonuria: Current Perspectives.
    Zatkova A; Ranganath L; Kadasi L
    Appl Clin Genet; 2020; 13():37-47. PubMed ID: 32158253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urine homogentisic acid and tyrosine: simultaneous analysis by liquid chromatography tandem mass spectrometry.
    Hughes AT; Milan AM; Christensen P; Ross G; Davison AS; Gallagher JA; Dutton JJ; Ranganath LR
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jul; 963():106-12. PubMed ID: 24952314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an in vitro model to investigate joint ochronosis in alkaptonuria.
    Tinti L; Taylor AM; Santucci A; Wlodarski B; Wilson PJ; Jarvis JC; Fraser WD; Davidson JS; Ranganath LR; Gallagher JA
    Rheumatology (Oxford); 2011 Feb; 50(2):271-7. PubMed ID: 20952450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new light on Alkaptonuria: A Fourier-transform infrared microscopy (FTIRM) and low energy X-ray fluorescence (LEXRF) microscopy correlative study on a rare disease.
    Mitri E; Millucci L; Merolle L; Bernardini G; Vaccari L; Gianoncelli A; Santucci A
    Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt A):1000-1008. PubMed ID: 28192171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolomic studies in the inborn error of metabolism alkaptonuria reveal new biotransformations in tyrosine metabolism.
    Norman BP; Davison AS; Hughes JH; Sutherland H; Wilson PJ; Berry NG; Hughes AT; Milan AM; Jarvis JC; Roberts NB; Ranganath LR; Bou-Gharios G; Gallagher JA
    Genes Dis; 2022 Jul; 9(4):1129-1142. PubMed ID: 35685462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raman Spectroscopy identifies differences in ochronotic and non-ochronotic cartilage; a potential novel technique for monitoring ochronosis.
    Taylor AM; Jenks DD; Kammath VD; Norman BP; Dillon JP; Gallagher JA; Ranganath LR; Kerns JG
    Osteoarthritis Cartilage; 2019 Aug; 27(8):1244-1251. PubMed ID: 31022456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alkaptonuria: a very rare metabolic disorder.
    Aquaron R
    Indian J Biochem Biophys; 2013 Oct; 50(5):339-44. PubMed ID: 24772955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatobiliary circulation and dominant urinary excretion of homogentisic acid in a mouse model of alkaptonuria.
    Norman BP; Sutherland H; Wilson PJM; Rutland DA; Milan AM; Hughes AT; Davison AS; Khedr M; Jarvis JC; Gallagher JA; Bou-Gharios G; Ranganath LR
    J Inherit Metab Dis; 2024 Jul; 47(4):664-673. PubMed ID: 38487984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: Analysis of data from the United Kingdom National Alkaptonuria Centre.
    Ranganath LR; Milan AM; Hughes AT; Khedr M; Davison AS; Wilson PJ; Dillon JP; West E; Gallagher JA
    JIMD Rep; 2020 Sep; 55(1):75-87. PubMed ID: 32904992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloidosis in alkaptonuria.
    Millucci L; Braconi D; Bernardini G; Lupetti P; Rovensky J; Ranganath L; Santucci A
    J Inherit Metab Dis; 2015 Sep; 38(5):797-805. PubMed ID: 25868666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interference of hydroxyphenylpyruvic acid, hydroxyphenyllactic acid and tyrosine on routine serum and urine clinical chemistry assays; implications for biochemical monitoring of patients with alkaptonuria treated with nitisinone.
    Curtis SL; Norman BP; Milan AM; Gallagher JA; Olsson B; Ranganath LR; Roberts NB
    Clin Biochem; 2019 Sep; 71():24-30. PubMed ID: 31228435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pigmentation Chemistry and Radical-Based Collagen Degradation in Alkaptonuria and Osteoarthritic Cartilage.
    Chow WY; Norman BP; Roberts NB; Ranganath LR; Teutloff C; Bittl R; Duer MJ; Gallagher JA; Oschkinat H
    Angew Chem Int Ed Engl; 2020 Jul; 59(29):11937-11942. PubMed ID: 32219972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alkaptonuria is a novel human secondary amyloidogenic disease.
    Millucci L; Spreafico A; Tinti L; Braconi D; Ghezzi L; Paccagnini E; Bernardini G; Amato L; Laschi M; Selvi E; Galeazzi M; Mannoni A; Benucci M; Lupetti P; Chellini F; Orlandini M; Santucci A
    Biochim Biophys Acta; 2012 Nov; 1822(11):1682-91. PubMed ID: 22850426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment.
    Ranganath LR; Milan AM; Hughes AT; Dutton JJ; Fitzgerald R; Briggs MC; Bygott H; Psarelli EE; Cox TF; Gallagher JA; Jarvis JC; van Kan C; Hall AK; Laan D; Olsson B; Szamosi J; Rudebeck M; Kullenberg T; Cronlund A; Svensson L; Junestrand C; Ayoob H; Timmis OG; Sireau N; Le Quan Sang KH; Genovese F; Braconi D; Santucci A; Nemethova M; Zatkova A; McCaffrey J; Christensen P; Ross G; Imrich R; Rovensky J
    Ann Rheum Dis; 2016 Feb; 75(2):362-7. PubMed ID: 25475116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revisiting Quantification of Phenylalanine/Tyrosine Flux in the Ochronotic Pathway during Long-Term Nitisinone Treatment of Alkaptonuria.
    Ranganath LR; Hughes AT; Davison AS; Khedr M; Imrich R; Rudebeck M; Olsson B; Norman BP; Bou-Gharios G; Gallagher JA; Milan AM
    Metabolites; 2022 Sep; 12(10):. PubMed ID: 36295821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.